Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study
Véronique Dièras(Institut Curie), Lorenzo Gianni, M Green(Sunnybrook Health Science Centre), Byung Mo Kang(Sunnybrook Health Science Centre), Jian Xu(University of California, Los Angeles), Mark D. Pegram(Stanford University), Shivani Verma(Govind Ballabh Pant University of Agriculture and Technology), Kim T. Blackwell(University of Iowa), David Miles(Sunnybrook Health Science Centre), José Baselga(Novartis (Switzerland)), IE Krop(Sunnybrook Health Science Centre), Manfred Welslau(Praxis für Hämatologie und Onkologie)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k